Edition:
United Kingdom

AC Immune SA (ACIU.OQ)

ACIU.OQ on NASDAQ Stock Exchange Global Market

11.55USD
11 Dec 2018
Change (% chg)

-- (--)
Prev Close
$11.55
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
26,145
52-wk High
$17.39
52-wk Low
$7.21

Latest Key Developments (Source: Significant Developments)

AC Immune Q3 IFRS Loss Per Share CHF 0.21
Tuesday, 13 Nov 2018 

Nov 13 (Reuters) - AC Immune SA ::AC IMMUNE REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS AND CORPORATE UPDATE.Q3 REVENUE CHF 2.3 MILLION.Q3 REVENUE VIEW CHF 1 MILLION -- THOMSON REUTERS I/B/E/S.PERIOD END CASH POSITION OF APPROXIMATELY CHF 200 MILLION THAT IS EXPECTED TO EXTEND OUR CASH RUNWAY TO Q3 2021.QTRLY ADJUSTED LOSS PER SHARE CHF 0.18.QTRLY IFRS LOSS PER SHARE CHF 0.21.  Full Article

AC Immune Q2 IFRS Loss Per Share CHF 0.19
Wednesday, 8 Aug 2018 

Aug 8 (Reuters) - AC Immune SA ::AC IMMUNE REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS AND CORPORATE UPDATE.Q2 REVENUE CHF 2.0 MILLION.QTRLY IFRS LOSS PER SHARE - BASIC AND DILUTED CHF 0.19.QTRLY NON-IFRS LOSS PER SHARE - BASIC AND DILUTED CHF 0.19.  Full Article

AC Immune Announces Offerings And Issuance Of Up To 10 Mln Common Shares
Tuesday, 17 Jul 2018 

July 17 (Reuters) - AC Immune SA ::AC IMMUNE ANNOUNCES OFFERINGS AND ISSUANCE OF UP TO 10 MILLION COMMON SHARES.AC IMMUNE SA - COMMENCING OFFERINGS OF UP TO 10 MILLION NEW COMMON SHARES OF CO WITH A NOMINAL VALUE OF CHF 0.02 EACH.AC IMMUNE SA - INTENDS TO ISSUE ALL NEW COMMON SHARES AGAINST CASH CONTRIBUTIONS AS APPROVED BY COMPANY'S SHAREHOLDERS.AC IMMUNE SA - PLANS TO USE PROCEEDS FROM OFFERINGS PRIMARILY TO FUND RESEARCH & DEVELOPMENT EXPENSES FOR CO'S CLINICAL AND PRE-CLINICAL RESEARCH.  Full Article

AC Immune Reports Q1 Revenue CHF 1.5 Million
Wednesday, 2 May 2018 

May 2 (Reuters) - AC Immune SA ::AC IMMUNE REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND CORPORATE UPDATE.Q1 REVENUE CHF 1.5 MILLION.Q1 REVENUE VIEW CHF 2 MILLION -- THOMSON REUTERS I/B/E/S.QTRLY NON-IFRS EPS LOSS CHF 0.19.  Full Article

AC Immune SA reports quarterly ‍loss per share CHF 0.15
Monday, 13 Nov 2017 

Nov 13 (Reuters) - AC Immune SA ::AC Immune SA reports third quarter 2017 financial results and corporate update.AC Immune SA qtrly ‍loss per share CHF 0.15 .Says qtrly adjusted loss per share CHF ‍0.16​.  Full Article

AC Immune to get milestone payment for Alzheimer drug
Thursday, 2 Nov 2017 

Nov 2 (Reuters) - AC Immune Ltd :Says to receive milestone payment for anti-tau antibody moving into phase 2 trial for Alzheimer's disease ‍​.Says upon the dosing of the first patient in the phase 2 clinical trial, AC Immune becomes eligible to receive a milestone payment of CHF 14 million, which is expected to be paid in the fourth quarter of 2017‍​.Says this will be the third milestone payment under the 2012 strategic collaboration and licensing agreement with Genentech.  Full Article

AC Immune SA to receive milestone payment for anti-tau antibody moving into phase 2 trial for alzheimer's disease
Thursday, 2 Nov 2017 

Nov 2 (Reuters) - Ac Immune Ltd :AC Immune SA to receive milestone payment for anti-tau antibody moving into phase 2 trial for Alzheimer's Disease.Ac Immune - ‍upon dosing of first patient in phase 2 trial of RO7105705​, co becomes eligible to get milestone payment of CHF 14 million, expected in Q4 2017.  Full Article

Essex Bio-Technology enters research project deal with AC Immune
Monday, 22 May 2017 

May 22 (Reuters) - Essex Bio-technology Ltd <1061.HK>:Company entered into research project agreement with ACI.Deal to collaborate in pre-clinical and clinical co-development of novel biological therapeutic to treat neurodegenerative diseases.  Full Article

BRIEF-AC Immune Says Co's Selling Shareholder May Sell Up To 18 Mln Common Shares

* AC IMMUNE SAYS CO'S SELLING SHAREHOLDER MAY SELL UP TO 18 MILLION COMMON SHARES Source text: (https://bit.ly/2P0dXMm) Further company coverage: